This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.
Age ranged from 18 to 75 years old (inclusive), regardless of gender;
Pathological diagnosis as sqNSCLC, with EGFR highly expressed, without other driver genes
Tumor tissue available for central laboratory testing;
Disease progression after prior anti PD-1/PD-L1 and platinum containing chemotherapy
Previously used anti EGFR, or docetaxel;
Central nervous system metastasis or meningeal metastasis;
Patients with high risk of bleeding due to tumor invasion of important arteries;
Uncontrolled or requiring repeated drainage of pleural effusion, pericardial effusion, or abdominal effusion;